# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

#### **SCHEDULE 13G/A**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

## VIGIL NEUROSCIENCE, INC.

(Name of Issuer)
Common Stock, par value \$0.0001 per share
(Title of Class of Securities)
92673K108
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1034 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other previous of the Act (however, see the

of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 92673K108	SCHEDULE 13G/A	Page 2 of 9 Pages
---------------------	----------------	-------------------

1	NAME OF REPORTING PERSONS				
	Deep Track Capital, LP				
2	CHECK THE API (a) □	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) □ (b) ⊠				
3 SEC USE ONLY					
3					
4	CITIZENSHIP OF	R PLACE	OF ORGANIZATION		
4	Delaware				
		_	SOLE VOTING POWER		
NII 1	MDED OF	5	0		
	MBER OF HARES		SHARED VOTING POWER		
	EFICIALLY VNED BY	6	3,649,726		
	EACH		SOLE DISPOSITIVE POWER		
REPORTING PERSON		7	0		
	WITH	_	SHARED DISPOSITIVE POWER		
		8	3,649,726		
0	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	3,649,726*				
1.0	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
10					
1.1	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	9.62%				
1.0	TYPE OF REPOR	TING PE	RSON		
12	IA OO				

<sup>\*</sup> Includes 2,054,795 pre-funded warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of this pre-funded warrant, and the holder shall not have the right to exercise any portion of this pre-funded warrant, pursuant to the terms and conditions of this pre-funded warrant, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Ordinary Shares outstanding immediately after giving effect to such exercise.

CUSIP No. 92673K108	SCHEDULE 13G/A	Page 3 of 9 Pages
CUSIP No. 92673K108	SCHEDULE 13G/A	Page 3 of 9 Pag

1	NAME OF REPORTING PERSONS			
	Deep Track Biotechnology Master Fund, Ltd.			
2	CHECK THE API (a) □	PROPRIA	TE BOX IF A MEMBER OF A GROUP	
2	(a) □ (b) ⊠			
3 SEC USE ONLY				
3				
4	CITIZENSHIP OF	R PLACE	OF ORGANIZATION	
4	Cayman Islands			
		5	SOLE VOTING POWER	
NILT	MDED OF	3	0	
S	MBER OF HARES		SHARED VOTING POWER	
	EFICIALLY VNED BY	6	3,649,726	
	EACH		SOLE DISPOSITIVE POWER	
REPORTING PERSON		7	0	
	WITH	0	SHARED DISPOSITIVE POWER	
		8	3,649,726	
0	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9	3,649,726*			
1.0	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
10				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11	9.62%			
1.2	TYPE OF REPOR	TING PE	RSON	
12	co			

<sup>\*</sup> Includes 2,054,795 pre-funded warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of this pre-funded warrant, and the holder shall not have the right to exercise any portion of this pre-funded warrant, pursuant to the terms and conditions of this pre-funded warrant, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Ordinary Shares outstanding immediately after giving effect to such exercise.

CUSIP No. 92673K108	SCHEDULE 13G/A	Page 4 of 9 Pages
CUSIP No. 92673K108	SCHEDULE 13G/A	Page 4 of 9 Page

1	NAME OF REPO	RTING PI	ERSONS		
1	David Kroin				
2	CHECK THE API (a) □	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(b) ⊠				
3	SEC USE ONLY				
3					
4	CITIZENSHIP OF	R PLACE	OF ORGANIZATION		
4	United States				
		5	SOLE VOTING POWER		
NILI	MDED OF	3	0		
S	MBER OF HARES	(	SHARED VOTING POWER		
	EFICIALLY VNED BY	6	3,649,726		
	EACH PORTING	_	SOLE DISPOSITIVE POWER		
REPORTING PERSON		7	0		
	WITH	0	SHARED DISPOSITIVE POWER		
		8	3,649,726		
0	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	3,649,726*				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □				
10					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	9.62%				
12	TYPE OF REPOR	TING PE	RSON		
12	IN HC				

<sup>\*</sup> Includes 2,054,795 pre-funded warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of this pre-funded warrant, and the holder shall not have the right to exercise any portion of this pre-funded warrant, pursuant to the terms and conditions of this pre-funded warrant, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Ordinary Shares outstanding immediately after giving effect to such exercise.

CUSI	P No. 92673K108	SCHEDULE 13G/A	Page 5 of 9 Pages		
Item 1.	(a) Name of Issuer				
	VIGIL NEUROSCIENCE, INC.				
Item 1.	(b) Address of Issuer's Principal Exc	ecutive Offices			
	100 Forge Road, Suite 700				
	Watertown, MA 02472				
Item 2.	(a) Names of Persons Filing:				
	<ul><li>(i) Deep Track Capital, LP</li><li>(ii) Deep Track Biotechnology Mas</li><li>(iii) David Kroin</li></ul>	ter Fund, Ltd.			
Item 2.	(b) Address of Principal Business O	ffice:			
		Greenwich, CT 06830 190 Elgin Ave, George Town, KY1-9001, Cayman Islands O Greenwich Ave, 3rd Floor, Greenwich, CT 06830			
Item 2.	(c) Citizenship:				
	<ul><li>(i) Delaware</li><li>(ii) Cayman Islands</li><li>(iii) United States</li></ul>				
Item 2.	(d) Title of Class of Securities				
	Common Stock, par value \$0.0001	per share (the "Common Stock")			
Item 2.	(e) CUSIP No.:				
	92673K108				
CUSI	P No. 92673K108	SCHEDULE 13G/A	Page 6 of 9 Pages		
Item 3.	-	§§240.13d-1(b) or 240.13d-2(b) or (c), check whether the presection 15 of the Act (15 U.S.C. 78o);	erson filing is a:		
(b)					
(c)	****	section 3(a)(19) of the Act (15 U.S.C. 78c);			
(d)	• •	der section 8 of the Investment Company Act of 1940 (15 U.S	S.C. 80a-8):		
	☐ An investment adviser in accordan		,,		
(f)		wment fund in accordance with §240.13d-1(b)(1)(ii)(F);			
(g)	☐ A parent holding company or cont	rol person in accordance with §240.13d-1(b)(1)(ii)(G);			
(h)	☐ A savings associations as defined	in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C	C. 1813);		
(i)	(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);				
(j)	☐ A non-U.S. institution in accordan	ce with \$240.13d-1(b)(1)(ii)(J);			
(k)	☐ A group, in accordance with §240 specify the type of institution:	.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accord	ance with §240.13d-1(b)(1)(ii)(J), please		
Not Ap	plicable				
CUSI	P No. 92673K108	SCHEDULE 13G/A	Page 7 of 9 Pages		

Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2023, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on 37,932,216 Common Stock outstanding.

#### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

#### Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

### Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

#### Item 8. Identification and Classification of Members of the Group

Not Applicable.

#### Item 9. Notice of Dissolution of Group

Not Applicable.

#### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

#### Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the

Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

**David Kroin** 

By: /s/ David Kroin

David Kroin

Exhibit I

#### JOINT FILING STATEMENT

#### PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: February 14, 2024

#### Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

**David Kroin** 

By: /s/ David Kroin

David Kroin